# A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

> **NCT01311687** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 455 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01311687
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-11
- **Primary completion:** 2013-03-01
- **Final completion:** 2017-08-29
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01311687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01311687, "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01311687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*